NASARIX™: Polyrizon’s Drug-Free Allergy Blocker Advances Towards Clinical Trials
Raanana, Israel – February 18, 2026 – Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical stage biotechnology company, has completed the branding process for its lead intranasal allergy product, now officially named NASARIX™. This development marks a significant step towards potential commercialization of the innovative, drug-free allergy blocker.
Addressing the Growing Allergy Epidemic
Allergic rhinitis, commonly known as hay fever, affects an estimated 10–30% of the global population 1. Symptoms like sneezing, nasal congestion, and itching significantly impact daily life, work, and sleep. The prevalence of allergies is increasing due to factors such as urbanization, pollution, and climate change-driven pollen increases 1. In the United States alone, over 60 million people are affected annually 1.
NASARIX™: A Novel Approach to Allergy Relief
NASARIX™ is based on Polyrizon’s proprietary Capture and Contain™ (C&C) hydrogel technology 4. This intranasal spray is designed to create a protective physical barrier against allergens, preventing them from contacting the nasal mucosa. Unlike many existing treatments, NASARIX™ offers a drug-free, non-pharmacological solution, avoiding the use of steroids, antihistamines, and their associated systemic effects 1. The product is as well formulated to be hydrating and comfortable for prolonged use 1.
Promising Preclinical Data and Regulatory Pathway
Preclinical laboratory data suggests that NASARIX™ demonstrates a superior allergen-blocking capacity compared to standard barriers, such as hydroxypropyl methylcellulose 4. Polyrizon has completed trademark screening for NASARIX™ in the U.S. And European markets 1, 3. The company is positioning NASARIX™ as a medical device, which offers a potentially faster and more efficient approval pathway compared to traditional drug development 4.
Recent Milestones and Future Outlook
In early 2026, Polyrizon initiated a human factors and usability study, fully aligned with FDA recommendations, to validate the clarity of product instructions and labeling 1. The company plans to commence clinical trials in the third quarter of 2026 4. With the global allergic rhinitis treatment market projected to reach USD 18.81 billion by 2035 1, NASARIX™ aims to provide a preventative and comfortable solution for allergy sufferers.
Worth a look